These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

549 related articles for article (PubMed ID: 17047046)

  • 21. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.
    Cairncross JG; Ueki K; Zlatescu MC; Lisle DK; Finkelstein DM; Hammond RR; Silver JS; Stark PC; Macdonald DR; Ino Y; Ramsay DA; Louis DN
    J Natl Cancer Inst; 1998 Oct; 90(19):1473-9. PubMed ID: 9776413
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Co-deletion of 1p/19q as Prognostic and Predictive Biomarker for Patients in West Bohemia with Anaplastic Oligodendroglioma.
    Polivka J; Polivka J; Repik T; Rohan V; Hes O; Topolcan O
    Anticancer Res; 2016 Jan; 36(1):471-6. PubMed ID: 26722084
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Correlation of chromosome 1p and 19q status and expression of R132H mutant IDH1 protein in oligodendroglial tumors].
    Yao K; Duan Z; Hu Z; Bian Y; Qi X
    Zhonghua Bing Li Xue Za Zhi; 2014 Oct; 43(10):663-7. PubMed ID: 25567591
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumour necrosis and microvascular proliferation are associated with 9p deletion and CDKN2A alterations in 1p/19q-deleted oligodendrogliomas.
    Godfraind C; Rousseau E; Ruchoux MM; Scaravilli F; Vikkula M
    Neuropathol Appl Neurobiol; 2003 Oct; 29(5):462-71. PubMed ID: 14507338
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chromosome 1p and 19q status and p53 and p16 expression patterns as prognostic indicators of oligodendroglial tumors: a clinicopathological study using fluorescence in situ hybridization.
    Jeon YK; Park K; Park CK; Paek SH; Jung HW; Park SH
    Neuropathology; 2007 Feb; 27(1):10-20. PubMed ID: 17319279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas.
    Bauman GS; Ino Y; Ueki K; Zlatescu MC; Fisher BJ; Macdonald DR; Stitt L; Louis DN; Cairncross JG
    Int J Radiat Oncol Biol Phys; 2000 Oct; 48(3):825-30. PubMed ID: 11020580
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial.
    van den Bent MJ; Carpentier AF; Brandes AA; Sanson M; Taphoorn MJ; Bernsen HJ; Frenay M; Tijssen CC; Grisold W; Sipos L; Haaxma-Reiche H; Kros JM; van Kouwenhoven MC; Vecht CJ; Allgeier A; Lacombe D; Gorlia T
    J Clin Oncol; 2006 Jun; 24(18):2715-22. PubMed ID: 16782911
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of genotype on outcome in oligodendroglioma: validation of the loss of chromosome arm 1p as an important factor in clinical decision making.
    Kanner AA; Staugaitis SM; Castilla EA; Chernova O; Prayson RA; Vogelbaum MA; Stevens G; Peereboom D; Suh J; Lee SY; Tubbs RR; Barnett GH
    J Neurosurg; 2006 Apr; 104(4):542-50. PubMed ID: 16619658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chromosome 1p and 19q deletions in malignant glioneuronal tumors with oligodendroglioma-like component.
    Takeuchi H; Kubota T; Kitai R; Matsuda K; Hashimoto N; Sato K
    J Neurooncol; 2009 Jan; 91(1):33-8. PubMed ID: 18781279
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Loss of genetic material within 1p and 19q chromosomal arms in low grade gliomas of central nervous system.
    Ręcławowicz D; Stempniewicz M; Biernat W; Limon J; Słoniewski P
    Folia Neuropathol; 2013; 51(1):26-32. PubMed ID: 23553134
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study.
    Ahluwalia MS; Xie H; Dahiya S; Hashemi-Sadraei N; Schiff D; Fisher PG; Chamberlain MC; Pannullo S; Newton HB; Brewer C; Wood L; Prayson R; Elson P; Peereboom DM
    J Neurooncol; 2015 Mar; 122(1):111-9. PubMed ID: 25534576
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402.
    Giannini C; Burger PC; Berkey BA; Cairncross JG; Jenkins RB; Mehta M; Curran WJ; Aldape K
    Brain Pathol; 2008 Jul; 18(3):360-9. PubMed ID: 18371182
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fluorescence in situ hybridization for 1p, 19q status in a cohort of glial neoplasms.
    Singh VY; Chacko G; Chacko AG; Rajshekhar V
    Neurol India; 2014; 62(1):32-6. PubMed ID: 24608451
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical significance of chromosome 1p/19q loss of heterozygosity and Sox17 expression in oligodendrogliomas.
    Li J; Miao N; Liu M; Cui W; Liu X; Li X; Shi X; Qing S; Ma Y; Zhang W; Biekemituofu H
    Int J Clin Exp Pathol; 2014; 7(12):8609-15. PubMed ID: 25674225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor cell-specific chromosomal abnormality in the vascular endothelial cells of anaplastic oligodendroglioma.
    Jiang H; Zhang Z; Ren X; Zeng W; Wang J; Lin S
    J Neurosurg; 2016 Oct; 125(4):995-1001. PubMed ID: 26771849
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Loss of heterozygosity of chromosome 1p/19q and p53 protein expression in oligodendroglioma].
    Xiong J; Liu Y; Li C; Zhu JJ; Ye ZR; Mao Y; Wang Y
    Zhonghua Bing Li Xue Za Zhi; 2009 Jul; 38(7):445-50. PubMed ID: 19781190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?
    Weller M; Berger H; Hartmann C; Schramm J; Westphal M; Simon M; Goldbrunner R; Krex D; Steinbach JP; Ostertag CB; Loeffler M; Pietsch T; von Deimling A;
    Clin Cancer Res; 2007 Dec; 13(23):6933-7. PubMed ID: 18056167
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular imaging of 1p/19q deletion in oligodendroglial tumours with 11C-methionine positron emission tomography.
    Iwadate Y; Shinozaki N; Matsutani T; Uchino Y; Saeki N
    J Neurol Neurosurg Psychiatry; 2016 Sep; 87(9):1016-21. PubMed ID: 26848169
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Favorable long-term outcome of low-grade oligodendrogliomas irrespective of 1p/19q status when treated without radiotherapy.
    Iwadate Y; Matsutani T; Hasegawa Y; Shinozaki N; Higuchi Y; Saeki N
    J Neurooncol; 2011 May; 102(3):443-9. PubMed ID: 20721680
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High rate of deletion of chromosomes 1p and 19q in insular oligodendroglial tumors.
    Wu A; Aldape K; Lang FF
    J Neurooncol; 2010 Aug; 99(1):57-64. PubMed ID: 20035368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.